CN103450172A - Preparation method of antipsychotic drug lurasidone - Google Patents
Preparation method of antipsychotic drug lurasidone Download PDFInfo
- Publication number
- CN103450172A CN103450172A CN2012101754064A CN201210175406A CN103450172A CN 103450172 A CN103450172 A CN 103450172A CN 2012101754064 A CN2012101754064 A CN 2012101754064A CN 201210175406 A CN201210175406 A CN 201210175406A CN 103450172 A CN103450172 A CN 103450172A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- described method
- reaction
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C[C@]1(COS(C)(=O)=O)C(C*)CCCC1 Chemical compound C[C@]1(COS(C)(=O)=O)C(C*)CCCC1 0.000 description 1
- XDODWINGEHBYRT-YUMQZZPRSA-N OC[C@H]1[C@H](CO)CCCC1 Chemical compound OC[C@H]1[C@H](CO)CCCC1 XDODWINGEHBYRT-YUMQZZPRSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention relates to preparation methods of (3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazole-3-yl)piperazinyl-1-methyl]cyclohexyl methyl}hexahydro-1H-4,7-methano-isoindole-1,3-dione (a compound represented by a formula I) and intermediates thereof. A hydrochloride (lurasidone hydrochloride) of the compound represented by the formula (I) can be used as a drug for treatment of psychosis.
Description
Technical field
The present invention relates to a kind of (3aR, 4S, 7R, 7aS)-2-{ (1R, 2R)-2-[4-(1,2-benzisothiazole-3-yl) piperazine-1-methyl] cyclohexyl methyl } six hydrogen-1H-4,7-methyl isoindole-1, the preparation method of 3-diketone (formula I compound) and intermediate thereof.
Background technology
Lurasidone HCl (Lurasidone hydrochloride, commodity are called Latuda) be that it is to serotonin 2A(5-HT2A by the antipsychotic agent with dual function of SUMITOMO CHEMICAL drugmaker exploitation) and d2 dopamine receptor all there is high affinity.The insane positive and recessive symptom are all had to obvious curative effects.Reported the synthetic route of formula (I) in JP 2006169155, with (1R, 2R)-1, 2-cyclohexanedimethanol two methanesulfonates formula (III) compounds are starting raw material, in toluene, reflux obtains methylsulfonic acid quaternary ammonium salt formula V, the quaternary ammonium salt obtained and (3aR, 4S, 7R, 7aS)-4, 7-methylene radical-1H-isoindole-1, 3-2H-bis-keto-acids (VI) reaction, make alkali in reflux in toluene with salt of wormwood, obtain target product (3aR, 4S, 7R, 7aS)-2-{ (1R, 2R)-2-[4-(1, 2-benzisothiazole-3-yl) piperazine-1-methyl] cyclohexyl methyl } six hydrogen-1H-4, 7-methyl isoindole-1, 3-diketone (formula I compound).But this method solvent for use toxicity is larger, unfriendly to environment, while easy generating portion by product when synthetic target product is done alkali in reflux in toluene with salt of wormwood, the existence of by product makes the purifying of target product be not easy operation, after making with extra care accordingly, to productive rate, can have a great impact, at US 2011263848A1, US2011263847A1 has carried out corresponding optimization to the problem existed, but still have by product to exist, and experimental implementation is more loaded down with trivial details, is difficult for carrying out suitability for industrialized production.
Summary of the invention
The problem existed for above prior art, the invention provides a kind of (3aR for preparing, 4S, 7R, 7aS)-2-{ (1R, 2R)-2-[4-(1,2-benzisothiazole-3-yl) piperazine-1-methyl] cyclohexyl methyl } six hydrogen-1H-4,7-methyl isoindole-1, the method for 3-diketone (formula I compound).The method is than the prior art easy handling, the experiment condition gentleness, and reaction product is easy to purifying, and productive rate is high, and product purity is good, is easy to realize the characteristics such as suitability for industrialized production.
The method comprises the following steps
By (1R, 2R)-1,2-CHDM formula (II) and methylsulfonyl chloride reaction, in methylene dichloride ,-20 ° of C ~ 20 ° C, react 5 ~ 24h, obtains formula (III) compound.
Formula (III) compound obtains methylsulfonic acid quaternary ammonium salt formula V compound with 3-(1-piperazinyl)-1,2 benzisothia triazole hydrochloride (formula IV compound) under heating condition.
By methylsulfonic acid quaternary ammonium salt formula V compound and (3aR, 4S, 7R, 7aS)-4,7-methylene radical-1H-isoindole-1,3-2H-bis-keto-acids (VI) reaction, obtain formula (I) compound.
As seen from the above technical solution, principal feature of the present invention is:
1. synthetic marketable material (1R, the 2R)-1,2-CHDM of choosing of formula (III) compound is starting raw material, and raw material is easy to get, and the reaction conditions gentleness of synthesis type (III) compound is easy to control, and productive rate is high, is easy to purifying.
2. methylsulfonic acid quaternary ammonium salt formula V compound is synthetic, and selecting acetonitrile is solvent, and reaction conditions is than the toluene gentleness, simple to operate.Obtain product purity high.
3. the synthetic employing DMF of formula (I) is excellent, and the purity of resulting product is high, productive rate is high, the needs of applicable suitability for industrialized production simple to operate, and selected solvent is environmentally friendly, on experiment operator, impact does not almost have, and toluene has great toxicity.
Embodiment
Following examples are to describe in detail the present invention, and unrestricted the present invention.
1. (1R, 2R)-1,2-CHDM two methanesulfonates formulas (III)
Add 500.0g (1R, 2R)-1,2-CHDM in the 10L there-necked flask, the 7500ml methylene dichloride adds triethylamine 1052.5g successively, methylsulfonyl chloride 835.0g, and after adding, reaction 8h.Add 3750ml purified water agitator treating in reaction system, separatory discards water layer, and organic phase is washed with dilute hydrochloric acid, then successively with saturated sodium bicarbonate washing, saturated common salt water washing, separatory, organic phase anhydrous sodium sulfate drying.The filtering anhydrous sodium sulphate, be evaporated to dry.Add wherein ether, suction filtration, 60 ℃ of lower forced air dryings of filter cake obtain off-white color solid 889.4g, yield: approximately 85.4%.
2. (3aR, 7aR)-4'-(1,2-benzisothiazole-3-yl) octahydro spiral shell [2H-isoindole-2,1'-piperazine] mesylate formula V
Add 885.0g (1R in the 20L reaction flask, 2R)-1,2-cyclohexanedimethanol two methanesulfonates formulas (III), 717.7g 3-(1-piperazinyl)-1,2 benzisothia triazole hydrochlorides (formula IV), 775.6g salt of wormwood, the 13.3L acetonitrile is heated with stirring to reflux and starts to reflux, stirring reaction.After reacting completely, filtered while hot, filter cake acetonitrile drip washing, filtrate decompression is concentrated into dry, obtains off-white color solid 1045.9g, yield approximately 88%.HPLC purity is greater than 99%.
3.(3aR, 4S, 7R, 7aS)-2-{ (1R, 2R)-2-[4-(1,2-benzisothiazole-3-yl) piperazine-1-methyl] cyclohexyl methyl } six hydrogen-1H-4,7-methyl isoindole-1,3-diketone (formula I compound)
The 10L there-necked flask adds 625.0g (3aR, 7aR)-4'-(1,2-benzisothiazole-3-yl) octahydro spiral shell [2H-isoindole-2, the 1'-piperazine] mesylate, 248.6g (3aR, 4S, 7R, 7aS)-4,7-methylene radical-1H-isoindole-1,3-2H-bis-keto-acids (VI), 611.8g salt of wormwood, 6250ml DMF, stirring heating heats up, 100 ° of C ~ 130 ° C of temperature control, reaction 36h.Stopped reaction, filtered while hot, filter cake DMF drip washing, filtrate is chilled to room temperature, drips wherein while stirring the 9375ml purified water, continues to stir 2h.Filter, filter cake is dry to the greatest extent with being evacuated to after purified water drip washing, and 55 ℃ of lower vacuum-dryings, obtain the 646g target product, yield 89%, and HPLC is greater than 95%.
Claims (9)
1. one kind prepares (3aR, 4S, 7R, 7aS)-2-{ (1R, 2R)-2-[4-(1,2-benzisothiazole-3-yl) piperazine-1-methyl] cyclohexyl methyl } six hydrogen-1H-4,7-methyl isoindole-1, the method for 3-diketone (formula I compound)
The method comprises the following steps
By the reaction of (1R, 2R)-1,2-CHDM formula (II) and methylsulfonyl chloride, in methylene dichloride-20 ℃ ~ 20 ℃, react 5 ~ 24h, obtain formula (III) compound
Formula (III) compound obtains methylsulfonic acid quaternary ammonium salt formula V compound with 3-(1-piperazinyl)-1,2 benzisothia triazole hydrochloride (formula IV compound) under heating condition
By methylsulfonic acid quaternary ammonium salt formula V compound and (3aR, 4S, 7R, 7aS)-4,7-methylene radical-1H-isoindole-1,3-2H-bis-keto-acids (VI) reaction, obtain formula (I) compound
。
2. according to the described method of right 1, it is characterized in that at synthesis type (III) solvent for use be methylene dichloride, alkali used is triethylamine or DIPEA.
3. according to the described method of right 2, the consumption of triethylamine or DIPEA be 2.2 ~ 5 equivalents with respect to compound formula (I), preferably 2.5 ~ 4.
4. according to the described method of right 2, the consumption of methylsulfonyl chloride be 1.9 ~ 3 equivalents with respect to compound formula (I), preferably 1.9 ~ 2.5.
5. according to the described method of right 1, it is characterized in that synthesis type (III) temperature of reaction-20 ℃ ~ 20 ℃, preferably-10 ℃ ~ 5 ℃, reaction times 5 ~ 24h, preferably 12 ~ 16h.
6. according to the described method of right 1, it is characterized in that at synthetic formula V solvent for use be acetonitrile, dimethylbenzene, DMF, the mixed solvent of N,N-dimethylacetamide or above solvent.
7. according to the described method of right 1, it is characterized in that at synthetic formula V alkali used be salt of wormwood, sodium carbonate, magnesiumcarbonate, 60 ℃ ~ 150 ℃ of temperature of reaction, preferably 80 ℃ ~ 120 ℃, reaction times 24h ~ 120h, preferably 60h ~ 96h.
8. according to the described method of right 1, it is characterized in that at synthesis type (I) solvent for use be DMF, N,N-dimethylacetamide, dioxane, the trimethyl carbinol, propyl carbinol, the mixed solvent of Virahol or above solvent.
9. according to the described method of right 1, it is characterized in that at synthesis type (I) alkali used be salt of wormwood, sodium carbonate, magnesiumcarbonate, calcium hydroxide, 60 ℃ ~ 150 ℃ of temperature of reaction, preferably 100 ℃ ~ 140 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101754064A CN103450172A (en) | 2012-05-30 | 2012-05-30 | Preparation method of antipsychotic drug lurasidone |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101754064A CN103450172A (en) | 2012-05-30 | 2012-05-30 | Preparation method of antipsychotic drug lurasidone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103450172A true CN103450172A (en) | 2013-12-18 |
Family
ID=49733058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101754064A Pending CN103450172A (en) | 2012-05-30 | 2012-05-30 | Preparation method of antipsychotic drug lurasidone |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103450172A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109553614A (en) * | 2017-09-27 | 2019-04-02 | 北京万全德众医药生物技术有限公司 | The preparation of Lurasidone isomer impurities |
| CN110734434A (en) * | 2019-11-19 | 2020-01-31 | 湖南洞庭药业股份有限公司 | Method for preparing lurasidone and salt thereof |
| CN112305096A (en) * | 2020-09-30 | 2021-02-02 | 辰欣药业股份有限公司 | Detection method of related substances of lurasidone hydrochloride tablets |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5532372A (en) * | 1990-07-06 | 1996-07-02 | Sumitomo Pharmaceuticals Company, Ltd. | Imide derivatives, and their production and use |
| US20110263847A1 (en) * | 2010-04-26 | 2011-10-27 | Dainippon Sumitomo Pharma Co, Ltd. | Process of a quaternary ammonium salt |
| US20110263848A1 (en) * | 2010-04-26 | 2011-10-27 | Dainippon Sumitomo Pharma Co., Ltd. | Process of a quaternary ammonium salt using phosphate |
-
2012
- 2012-05-30 CN CN2012101754064A patent/CN103450172A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5532372A (en) * | 1990-07-06 | 1996-07-02 | Sumitomo Pharmaceuticals Company, Ltd. | Imide derivatives, and their production and use |
| US20110263847A1 (en) * | 2010-04-26 | 2011-10-27 | Dainippon Sumitomo Pharma Co, Ltd. | Process of a quaternary ammonium salt |
| US20110263848A1 (en) * | 2010-04-26 | 2011-10-27 | Dainippon Sumitomo Pharma Co., Ltd. | Process of a quaternary ammonium salt using phosphate |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109553614A (en) * | 2017-09-27 | 2019-04-02 | 北京万全德众医药生物技术有限公司 | The preparation of Lurasidone isomer impurities |
| CN110734434A (en) * | 2019-11-19 | 2020-01-31 | 湖南洞庭药业股份有限公司 | Method for preparing lurasidone and salt thereof |
| CN110734434B (en) * | 2019-11-19 | 2022-11-11 | 湖南洞庭药业股份有限公司 | Method for preparing lurasidone and salt thereof |
| CN112305096A (en) * | 2020-09-30 | 2021-02-02 | 辰欣药业股份有限公司 | Detection method of related substances of lurasidone hydrochloride tablets |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105330609B (en) | A kind of method for preparing LCZ696 | |
| CN104844585A (en) | Preparation method of brexpiprazole | |
| CN104829602A (en) | Brexpiprazole preparation method | |
| WO2011160594A1 (en) | New preparation method of lapatinib | |
| CN107235959A (en) | A kind of novel method for synthesizing for preparing cancer therapy drug Niraparib | |
| CN104059025A (en) | Novel intermediate used for preparation of avanafil and preparation method thereof | |
| CN103450172A (en) | Preparation method of antipsychotic drug lurasidone | |
| CN105566215A (en) | Preparation method of Stivarga | |
| CN103724336B (en) | A kind of synthetic method of novel anticoagulation medicine | |
| CN104628679A (en) | New synthesis method and intermediate of Bitopertin | |
| CN104650093B (en) | Synthesis method of sildenafil analog | |
| CN105481856A (en) | Preparation method of palipefidone | |
| CN105566260B (en) | A kind of preparation method of frusemide | |
| CN107814804A (en) | The preparation method of Buddhist nun is replaced according to Shandong | |
| CN103588765A (en) | Synthesis method for azilsartan medoxomil or salt thereof, intermediate of azilsartan medoxomil or salt thereof and synthesis method for intermediate | |
| CN103130700B (en) | Preparation method of azelnidipine intermediate | |
| WO2022252789A1 (en) | Method for preparing jak inhibitor key intermediate | |
| CN113372329B (en) | Preparation method of fasudil hydrochloride compound | |
| CN106588921B (en) | A kind of synthetic method of the methyl formate of 7 azaindole 3 | |
| CN107266442A (en) | The preparation method of piperidines with antitumor activity and pyridine compounds and their | |
| CN103755636A (en) | Method for synthesizing Lorcaserin raceme derivative | |
| CN105272921A (en) | Method for preparing Ceritinib and intermediate compound of Ceritinib | |
| CN103058950A (en) | Preparation method of febuxostat | |
| CN104557877A (en) | Avanafil intermediate as well as preparation method and application thereof | |
| CN102633779A (en) | Fasudil acetate as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: GUANGDONG TRUSTEVER PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: GUANGZHOU YAOYUAN BIOLOG MEDICINE SCIENCE + TECHNOLOGY CO., LTD. Effective date: 20140307 |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510300 GUANGZHOU, GUANGDONG PROVINCE TO: 510627 GUANGZHOU, GUANGDONG PROVINCE |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20140307 Address after: 801 A tower, R & F Intime Plaza, 100 West Whampoa Road, Tianhe District, Guangzhou, Guangdong 510627, China Applicant after: Guangdong Trustever Pharmaceutical Co., Ltd. Address before: 510300, Guangzhou International Biological Island, No. three, No. 401, A fourth, Guangdong Applicant before: Guangzhou Yaoyuan Biological Medicine Science & Technology Co., Ltd. |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131218 |